Introduction
Unrelated cord blood transplant (CBT) has been demonstrated to be a valuable alternative option for children with malignancies who do not have an HLA-identical sibling donor. The advantages of using cord blood are:
(1) The immediate availability of the donor. This is a considerable advantage in children with high-risk leukemia who need a transplant as early as possible after reaching remission. A cord blood search and transplant can be performed in 1 month, while an unrelated BM donor search and transplant acquisition takes a median time of 3 months (National Marrow Donor Program (NMDP)). ( 2) The possible use of non-HLA-identical donor increases the possibility to transplant patients with rare haplotypes as usually the search is based on the number of cells and low-resolution typing for HLA-A and -B and allele typing for DRB1. (3) The current consensus is to use any donor with 0-2 HLA differences and a number of nucleated cells X3 Â 10 7 /kg. 1 This is in contrast with the current recommendations for an adult unrelated BMT where high-resolution typing must be performed for HLA-A, -C,-B, -DRB1 and -DQB1, and usually only 10/10 or 9/ 10 identical donors are accepted for transplant. With more than nine million HLA-typed unrelated BM donors worldwide, the probability to find a donor is approximately 50% and is strongly dependent on the ethnic origin of patients. Cord blood banks have been established, and they collected approximately 250 000 cord blood units and provided more than 10 000 allogeneic unrelated transplants allowing a doubling of the number of transplants as it is now very rare to deny a transplant to a patient in need because of the lack of donor. The recent possibility to use a double CBT has overcome the problem of a low cell dose. (4) The decrease of GvHD is due to the immune properties of cord blood cells, while it seems that the GvL effect is observed.
In this report, we will describe the results of CBT in children with acute leukemia and the results of the comparison with matched unrelated BMTs and with haploidentical family peripheral blood hematopoietic SCT.
Results of unrelated cord blood transplant in children with acute leukemia
Eurocord has collected data provided by 373 centers from 43 countries on 3372 unrelated CBTs, among which 1979 were given to pediatric patients. The EFS of 879 children with malignancies transplanted with a single cord blood unit was 45% ± 4 in first CR (CR1), 38% ± 3 in second CR (CR2) and 32% ± 3 in more advanced stage of the disease. 
AML
Eurocord has updated data on 159 children with AML; 28 were in CR1, 79 in CR2 and 47 in more advanced stage of the disease. EFS was 57% in CR1, 47% in CR2 and 22% in more advanced stage of the disease. Relapse incidence was 10% in CR1, 23% in CR2 and 61% in advanced disease. The stage of the disease and number of cells infused were the main prognostic factors.
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ALL
Eurocord has performed an analysis on 185 patients with ALL who received an unrelated CBT. LFS was 38% in CR1, 36% in CR2 and CR3, and 18% in advanced disease. From multivariate analysis, adverse factors associated with LFS were found to be advanced disease at the time of transplant, previous autologous or allogeneic transplant and centers performing less than 10 CBTs. Acute GvHD was associated with less relapse, and prevention of GvHD with MTX increased the RR. Center effect was an important factor for transplant-related mortality and disease-free survival; this was possibly associated with patient and donor selection criteria.
Comparison of unrelated cord blood transplants with alternative sources of stem cells in children
Pooled comparisons of studies of umbilical CBT (UCBT) and unrelated bone marrow transplantation (UBMT) in children found that the incidence of chronic GvHD was lower in UCBT (RR ¼ 0.26, confidence interval 0.12-0.57, P ¼ 0.16) but the incidence of grade III-IV acute GvHD did not differ (RR ¼ 1.04, confidence interval ¼ 0.42-5.03, P ¼ 0.55). [4] [5] [6] [7] There was no difference in 2-year overall survival in children when studies were pooled (RR ¼ 0.76, confidence interval ¼ 0.31-1.87, P ¼ 0.91). 8 Recently, M Eapen et al. 9 published a comparative study of outcomes of unrelated-donor umbilical cord blood and BM in children with acute leukemia. Outcomes of 503 children with acute leukemia transplanted with unrelated CBT were compared to the outcomes of 282 BM recipients. All transplants took place in the United States. Recipients of UCBT were transplanted with grafts that were HLA matched (n ¼ 35), or HLA mismatched for one (n ¼ 201) or two antigens (n ¼ 267) (typing at the antigen level for HLA-A and -B and allele level for HLA-DRB1). BM recipients were transplanted with grafts that were matched at the allele level for HLA-A, -B, -C and -DRB1 (n ¼ 116) or mismatched (n ¼ 166). The primary end point was 5-year LFS.
In comparison with allele-matched BMT, 5-year LFS was similar to that after UCBT mismatched for one or two antigens and possibly higher after HLA-matched UCBT.
Treatment-related mortality was slightly higher after two HLA-mismatched UCBTs (RR ¼ 2.31, P ¼ 0.0003) and possibly after one antigen HLA-mismatched low cell dose UCBT (RR ¼ 1.88, P ¼ 0.0455). RRs were lower after two antigen-mismatched UCBTs (RR ¼ 0.54, P ¼ 0.0045).
Eurocord and the pediatric working party of the EBMT preformed a study comparing outcomes of unrelated CBT and related haploidentical T-depleted CD34 cell transplant in children with high-risk acute leukemia. In this study, 127 children received a Haplo transplant and 341 an unrelated CBT. Patients' characteristics were quite similar concerning the disease and its status at transplant. All Haplo had at least two HLA differences; in the UCBT group, 17% were HLA 6/6 matched, 54% had one HLA mismatch, 28% had two HLA mismatches and 1% had three HLA mismatches. Engraftment rate was faster in the Haplo group at 14 days median granulocyte recovery compared to 26 days in the UCBT group (P ¼ 0.003). GvHD II-IV was 20% in the Haplo group and 39% in the UCBT group (P ¼ 0.001). There were no statistical differences between both groups with respect to transplant-related mortality (40%) and EFS (26%). RR was higher in the Haplo group (P ¼ 0.01). In this preliminary study, it was impossible to demonstrate any difference between both groups but many variables should be analyzed further including a more detailed study of center effects, as there was a considerable heterogeneity between centers practicing a high number of either type of transplants, while very few centers did both techniques. The number of patients per unit is also a considerable factor of heterogeneity of the results; centers performing a small number of transplants tended to have worse outcome. In all cases, a longer time of follow-up is necessary as it was only 20 months in both groups.
Conclusion
All these data support the concept that unrelated CBTs could be the preferred source of stem cells for transplantation in children with acute leukemia because of the increasing number of cord blood units collected worldwide and the immediate availability of the transplant allowing the transplant to be scheduled at the time of remission before the patient relapses. Most studies have shown that, in children, results are comparable or even better than with other sources of stem cells. Increasing cell dose and HLA matching might probably show the superiority of cord blood to other sources. According to these results, an algorithm for unrelated donor search is proposed in Figure 1 . Further progress is expected from new techniques for graft facilitation by using double CBTs or intrabone injection of cord blood.
